Gene G. Kinney, Ph.D., is the President and Chief Executive Officer at PROTHENA PLC, a clinical-stage biotechnology company focused on discovering and developing novel therapies for neurodegenerative and rare peripheral amyloid diseases. Dr. Kinney has been a pivotal figure in the company since joining in 2012, initially serving as the Chief Scientific Officer before being appointed President and CEO in 2016. Under his leadership, Prothena has made significant strides in advancing its pipeline of therapeutic candidates, particularly in the areas of Alzheimer's disease, ATTR amyloidosis, and Parkinson's disease. Before joining Prothena, Dr. Kinney held several leadership positions in the biopharmaceutical industry, showcasing his deep expertise in neuroscience drug discovery and development. He previously served as Vice President and Head of Neuroscience at Wyeth Pharmaceuticals, where he was instrumental in the development of several drug candidates. Dr. Kinney's academic credentials are equally impressive; he earned his Ph.D. in Neuroscience from the University of Colorado Health Sciences Center and completed his postdoctoral training at the University of Pennsylvania. His extensive experience and strategic vision have been crucial in steering Prothena towards its goal of delivering groundbreaking treatments to patients suffering from debilitating diseases. As CEO, Dr. Kinney has been committed to fostering a culture of innovation and scientific excellence at Prothena. His leadership has been marked by the successful advancement of multiple clinical programs, including the notable development of PRX002 for the treatment of Alzheimer's disease and PRX004 for ATTR amyloidosis. Dr. Kinney's dedication to translating cutting-edge research into tangible therapeutic solutions has not only elevated Prothena's standing in the biotech industry but also instilled hope in the global community affected by neurodegenerative and rare diseases.